With Aduhelm in tatters, the search is on for Michel Vounatsos’ replacement at Biogen; David Liu, Roger Perlmutter join insitro’s SAB

Michel Vounatsos

→ Because of the dearth of Alzheimer’s treatments, Biogen pushed aggressively to cross the regulatory goal line with aducanumab despite early trial wrap-ups and pervasive efficacy questions. The highly controversial approval of Aduhelm, and the calamitous rollout that followed, proved to...

Click to view original post